Rosetta Genomics (ROSG) Earning Somewhat Positive Press Coverage, Analysis Finds

Media headlines about Rosetta Genomics (NASDAQ:ROSG) have been trending somewhat positive recently, Accern reports. The research firm identifies positive and negative media coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Rosetta Genomics earned a media sentiment score of 0.16 on Accern’s scale. Accern also assigned news coverage about the medical research company an impact score of 44.9912676838996 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

Shares of Rosetta Genomics stock traded down $0.04 on Tuesday, hitting $0.35. The stock had a trading volume of 124,209 shares, compared to its average volume of 133,021. Rosetta Genomics has a 52-week low of $0.23 and a 52-week high of $3.29.

How to Become a New Pot Stock Millionaire

ROSG has been the subject of several recent analyst reports. ValuEngine raised Rosetta Genomics from a “strong sell” rating to a “sell” rating in a research note on Friday, February 2nd. Barrington Research lowered Rosetta Genomics from an “outperform” rating to a “market perform” rating in a report on Monday, December 18th.

In other news, major shareholder Healthcare Master Fund Sabby bought 119,761 shares of Rosetta Genomics stock in a transaction dated Thursday, March 15th. The stock was acquired at an average cost of $0.42 per share, with a total value of $50,299.62. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

TRADEMARK VIOLATION WARNING: “Rosetta Genomics (ROSG) Earning Somewhat Positive Press Coverage, Analysis Finds” was first published by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright legislation. The correct version of this report can be viewed at

Rosetta Genomics Company Profile

Rosetta Genomics Ltd. operates as a genomic diagnostics company worldwide. The company's microRNA technologies based diagnostic tests include RosettaGX Cancer Origin for the identification of the primary site of metastatic cancer; mi-KIDNEY, a kidney tumor classification test for pathology samples; RosettaGX Reveal for the diagnosis of indeterminate thyroid fine-needle aspirate samples; and mi-LUNG diagnostic tests.

Insider Buying and Selling by Quarter for Rosetta Genomics (NASDAQ:ROSG)

Receive News & Ratings for Rosetta Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rosetta Genomics and related companies with's FREE daily email newsletter.

Leave a Reply